Making the most out of the least: new insights into congenital diaphragmatic hernia Hratch L Karamanoukian, Stuart J O'Toole, Bruce A Holm, Philip L Glick Congenital diaphragmatic hernia (CDH) has an incidence hypertension in CDH, others have maintained that pulmonary hypertension is an avoidable iatrogenic comof between 1:2000 and 1:5000 live births.
1 A posterolateral diaphragmatic defect allows abdominal viscera to herniate plication caused by aggressive ventilation and chest drainage. 19 It is believed that increased transpulmonary into the thoracic cavity early in gestation, inhibiting normal fetal lung growth and development.
2 3 Other pathopressure causes perivascular emphysema and pulmonary hypertension (the "air block syndrome") with surfactant physiological features such as pulmonary hypertension, surfactant deficiency, and left ventricular hypoplasia may deficiency being the reason. Histological, morphological, and biochemical similarities act synergistically to produce a mortality exceeding 60% even in the era of extracorporeal membrane oxygenation. have been noted between the lungs of babies with respiratory distress syndrome and those with CDH. 20 Infants New insights into the pathophysiology of CDH will be reviewed and new treatment strategies emphasised.
diagnosed prenatally with CDH have immature lecithin sphingomyelin (L/S) ratios and reduced levels of phosphatidyl glycerol (PG) in the amniotic fluid. 21 22 The fetal lamb model of CDH has been shown to have a quantitative Pulmonary hypoplasia, pulmonary hypertension and qualitative reduction in lung surfactant 23 with reduced and surfactant deficiency total lung capacity and decreased compliance. A significant A considerable reduction in the number of bronchial diincrease in lung compliance, total lung capacity, and oxyvisions occurs during development which is more severe genation have been found in fetal CDH lambs treated on the ipsilateral side. 5 Bronchial divisions are arrested at prophylactically with surfactant (Infasurf; ONY Inc, 10-12 weeks on the side of the hernia and at 12-14 weeks Buffalo, New York, USA) 24 25 with a dramatic fall in pulon the contralateral side. This causes an overall reduction monary vascular resistance and subsequent increase in in the gas exchange area. In addition, the lungs appear to pulmonary blood flow. 26 This indicates that a portion of be arrested in the saccular phase of development. It has the pulmonary hypertension in CDH is due to alveolar been argued that many infants dying of CDH have "lethal instability and inadequate recruitment of all alveoli in a pulmonary hypoplasia". 6 However, this doesn't explain the non-compliant lung. "honeymoon period" during which they have adequate oxygenation and ventilation, but then deteriorate regardless of treatment.
6 Recently adopted "alveolar recruitment strategies" may help to explain this dichotomy.
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Selection criteria for antenatal therapy Timely fetal surgical correction of the diaphragmatic hernia The lungs of patients with CDH have been found to have a decrease in size of the vascular bed, 10 abnormal has been shown to reverse both the pulmonary hypoplasia and the pulmonary vascular abnormalities in CDH. 27 Semuscularisation of the acinar arteries, 10 and an increased sensitivity to stimuli of pulmonary vasoconstriction. 11 The lection criteria for in utero surgical correction of CDH remains ill defined. 28 29 It is still impossible to determine pulmonary vasculature cannot accept all of the right ventricular output at birth, resulting in the shunting of blood prospectively which fetuses with CDH will survive the gestational or neonatal period, as only these groups should across the ductus arteriosus and foramen ovale. Although there has been an intensive search for mediators that cause be candidates for repair of the diaphragmatic hernia in utero. The major challenge has been to identify prenatal pulmonary vasoconstriction in CDH, no single culprit has been identified. Endothelin-1, a potent vasoactive peptide, risk factors in the fetus that will accurately select potential candidates for fetal surgery. Antenatal diagnosis before 25 is increased during episodes of pulmonary hypertension, but the complicated actions of this protein make it difficult weeks gestation has been used as the sole indication for fetal surgery, based on the finding that prenatally diagnosed to determine whether it causes pulmonary vasoconstriction or is produced in response to it.
12 13 Increased thromboxane CDH is associated with a mortality of 88%. 30 Others have shown that fetal age at diagnosis, polyhydramnios, dilated levels have also been found with episodes of pulmonary hypertension, but again results are confusing and the clinstomach in the chest, and mediastinal shift are limited in their prognostic usefulness and do not assess "fetal lung ical significance unknown. [14] [15] [16] In addition, there is no evidence to suggest that there is a deficiency of nitric oxide function" or neonatal outcome. 25 27 31 However, the "hidden mortality" in CDH is not entirely due to aberrant lung (NO) production in CDH. Pulmonary nitric oxide synthase production has been shown to be identical in both surgically development. 29 32 Human necropsy studies and studies in the fetal lamb model have demonstrated left ventricular created CDH and control fetal lambs at term. 17 Nitric oxide synthase (NOS) activity was found to remain at "smallness" in CDH. 33 34 Prenatal echocardiography has shown that ventricular disproportion (decreased left ventcontrol levels following ventilation, suggesting that a deficiency of NO production does not contribute to the ricular to right ventricular internal diameter ratios) noted before 24 weeks gestation is associated with a 100% pathophysiology of pulmonary hypertension in the surgically created lamb model of CDH. 17 Interestingly, demortality. 35 36 It has been speculated that such structural data generated echocardiographically as early as the creased pulmonary NOS activity has been shown to be a pathophysiological feature in the nitrofen induced rat pseudoglandular stage of lung development may be helpful in identifying fetuses with CDH that have lethal pulmonary model of CDH.
18 Therefore, although an imbalance between vasodilators and vasoconstrictors has been hyhypoplasia. 37 Consequently, it has been suggested that the heart may be the "missing link" in the treatment algorithm pothesised to explain the pathophysiology of pulmonary group.bmj.com on June 25, 2017 -Published by http://thorax.bmj.com/ Downloaded from used to determine which fetuses should be considered for presence of pulmonary hypertension, and to measure left ventricular mass index and left-to-right shunt fraction, to be fetal surgery and which should be managed with state of the art postnatal care. 29 32 repeated as frequently as necessary to reassess pulmonary haemodynamics and identify the direction of ductal level Tracheal ligation, also referred to as "PLUG" (Plug the Lung Until it Grows), has been shown to reverse the shunting, if any. If pulmonary hypertension with rightto-left shunting, left ventricular dysfunction, or systemic pulmonary hypoplasia by accelerating fetal alveolar growth, and to reverse the pulmonary vascular abnormalities in hypotension exist, vigorous use of inotropic agents is suggested to improve left ventricular function, increase sys-CDH. 38 39 However, significantly decreased total phospholipid content by bronchoalveolar lavage and decreased temic blood pressure, and reverse the right-to-left shunt. Efforts should be made to prevent factors that have been surfactant synthesis by the type II pneumocytes in CDH have been described following tracheal ligation. 40 The shown to increase pulmonary vascular resistance -for example, hypoxia, hypercarbia, acidosis, and hypothermia. clinical significance of these findings remains unknown as most animal data have been limited to short periods
We recommend gentle mechanical ventilation during this period in order to maintain a postductal saturation above of study. 40 Long term studies are necessary to determine the clinical significance of these biochemical findings.
90%. The peak inspiratory pressure (PIP) should never exceed the steep portion of the pressure-volume (PV) curve generated by online pulmonary function machines (PEDS; MAS Inc, Philadelphia, Pennsylvania, USA). For each Postnatal therapy If conventional mechanical ventilation does not stabilise patient treated, individual PV data should be generated repeatedly to optimise ventilatory settings and to help avoid the neonate with CDH, then alternative methods of oxygenation and ventilation should be considered. The primbarotrauma to the hypoplastic and surfactant deficient lungs. Although more controversial, P 2 should be mainary abnormality of neonates with CDH who develop or maintain severe respiratory distress results from persistence tained at or below 8 kPa. No effort should be made to normalise P 2 at the expense of significant barotrauma, of the fetal circulation -increased pulmonary artery pressures, increased pulmonary vascular resistance, and rightwhich may further compromise the quantitative surfactant deficiency with proteinaceous and/or bloody exudate.
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to-left shunting at the foramen ovale and the ductus arteriosus. This results in a vicious cycle of hypercarbia, Some centres have advocated "permissive hypercapnia" which tolerates moderately high P 2 levels as long as a acidosis, and progressive hypoxaemia. Surfactant therapy has been advocated even when the L/S ratio is normal, as post-ductal arterial P 2 is maintained above 90%. 51 This strategy avoids overt barotrauma of the lungs. 51 52 In a bronchoalveolar lavage data have shown a qualitative and quantitative deficiency in surfactant phospholipids. 41 42 small, non-randomised series Wung et al reported survival of 94% using this technique, avoiding ECMO in 95% of Infasurf (ONY Inc, Buffalo, New York, USA) should be administered intratracheally in a dose of 100 mg/kg before their patients. 51 Kays et al have successfully used a similar strategy with a survival rate exceeding 94% compared with the first delivered breath.
23-25 43 44 Infasurf is a calf lung surfactant extract which includes surfactant associated pro-47% using standard therapy in combination with ECMO.
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Although less efficacious, neonates transferred to a terteins B and C. It has theoretical efficacy over the most commonly used artificial surfactant preparations Exosurf tiary care centre after a variable period of failed conventional mechanical ventilation should be considered for (Burroughs Wellcome, Research Triangle Park, North Carolina, USA) and Survanta (Beractant, Ross Laboratrescue with exogenous surfactant. Again, we recommend 100 mg/kg of a calf lung surfactant preparation given in a ories, Columbus, Ohio, USA). 45 Inhaled NO has been shown to improve oxygenation single dose with repeated doses if necessary. Need for continued gentle mechanical ventilation, support for inand survival in a lamb model of persistent pulmonary hypertension (PPHN). 46 Several case reports now indicate haled nitric oxide therapy, HFOV, or ECMO therapy should be considered once these neonates arrive at tertiary that inhaled NO may improve oxygenation in neonates with CDH.
7 47 48 Short term NO inhalation in CDH has care centres as they invariably have suffered significant barotrauma. been shown to improve oxygenation in neonates with CDH only after decannulation from extracorporeal membrane oxygenation (ECMO). It is speculated that this is related to maturation of the endogenous surfactant system during      It has been shown that a delayed surgical approach, en-ECMO. 8 In contrast to infants with CDH, those with PPHN respond dramatically to inhaled NO. 7 46 This disabling preoperative stabilisation of these critically ill neonates, decreases morbidity and mortality. 53-56 Several parity in response to inhaled NO lies in the unique pathophysiology of CDH.
8 9 It appears that exogenous surfactant reports now indicate that circulatory stability, respiratory mechanics, and gaseous exchange deteriorate after repair is required in the lamb model of CDH for delivery of inhaled NO to the terminal lung units, where it works of CDH. 53 55 56 It is therefore better to stabilise the patient before attempting surgical repair. Although the ideal time synergistically with exogenous surfactant to decrease intrapulmonary shunting and PAP. 9 Similar efficacy has been to repair the diaphragmatic hernia is unknown, it has been suggested that 24 hours after stabilisation is ideal but, in achieved with combination inhaled NO and high frequency oscillating ventilation (HFOV) or perfluorocarbon asfact, delays of up to 7-10 days are tolerated well. [57] [58] [59] It is probably prudent to operate on these neonates when sociated gas exchange (PAGE), probably for the same reason. 46 49 50 All these strategies emphasise alveolar reechocardiographic evidence for normal pulmonary artery pressures is maintained for at least 24-48 hours. 60 cruitment of the atelectatic, surfactant deficient lungs in CDH. Unless this strategy is utilised, NO may not be ECMO has become the final instrument to salvage the neonate with CDH who is refractory to conventional meddelivered to the alveolar capillary interface where it stimulates smooth muscle cell relaxation. ical management. 61 62 Although initial reports did not indicate improved survival with ECMO, more recent series have reported survival of 80-90%. 62 The timing of operation also remains a major issue as it relates to ECMO Neonatal resuscitation An echocardiogram should be performed early to detertherapy. The potential advantages of operating while on ECMO is based on the observation that postoperative mine if any structural abnormalities exist, to assess for the lung hypoplasia but of inadequate alveolar recruitment. 
